IVIEW Therapeutics Completed Successful IVW-1001-CS-101 Clinical Trial Kickoff Meeting and Expects to Initiate the Trial In Q2 2024

[Cranbury, NJ, April 11, 2024] IVIEW Therapeutics Inc., a clinical stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, announces that the company and its clinical CRO partner have successfully completed the clinical trial kickoff meeting on April 9, 2024 at IVIEW’s Cranbury New Jersey office. This marks a significant milestone in the effort to initiate the Phase 1/2 clinical trial in the second quarter of 2024. The trial will evaluate the Safety, Tolerability, and Efficacy of IVW-1001, a novel TRPM8 agonist, to treat signs and symptoms of dry eye diseases. IVIEW selected an ophthalmic-specific clinical CRO with deep experience managing early stage trials. The team members have been carefully trained, sites carefully selected based on past clinical trial performance, and study supplies prepared for distribution. This meticulous preparation sets the stage for the trial to commence in May 2024. Dry eye diseases represent a prevalent and burdensome condition affecting millions worldwide. IVW-1001, developed by IVIEW Therapeutics Inc., offers promising potential as a therapeutic intervention, leveraging its TRPM8 agonist mechanism to target the underlying causes of dry eye. The CRO representative commented that “IVIEW has been extremely careful in designing a protocol that leverages best practices with expected study endpoints.” The upcoming clinical trial will evaluate the safety and efficacy of IVW-1001, paving the way for potential breakthroughs in dry eye treatment. IVIEW Therapeutics looks forward to the journey ahead and eagerly anticipates the results of this critical project. About IVIEW Therapeutics Inc. IVIEW Therapeutics Inc. is a clinical stage biotechnology company focusing on innovative ophthalmic therapeutics. We are driven by the pursuit of innovative science that leads to differentiated products to fulfill unmet medical needs. We invest in novel mechanisms of action, and differentiated drug delivery technology platforms that allow us to bring forward assets with potentially superior target product profiles. The company's innovative portfolio of small molecules and gene therapy assets cover dry eye, myopia, conjunctivitis, glaucoma, presbyopia. iView is located in Cranbury, New Jersey with 11,045 sq. ft. laboratory and office space in the Princeton area. For additional information, please visit the Company’s website at www.iviewtherapeutics.com. For further inquiries or media contacts, please reach out to our team at [email protected].

The release as fetched from its publisher. iviewtherapeutics.com ↗